Table 1.
Characteristics of all the studies included in the meta-analysis
| Study | Year | Country | Time | No. | Age (years) | Index and cut-off | Median follow-up (month) | Outcome |
|---|---|---|---|---|---|---|---|---|
| Yasui | 2018 | Japan | 2011–2016 | 90 | 73.7 ± 0.9 | NLR: 3.76 | Unclear | OS |
| Fan | 2018 | China | 2013–2017 | 104 | 72 (65.3–77.0) | NLR: 3 | 20.2 | OS, PFS |
| Conteduca | 2018 | Italy | 2011–2016 | 551 | 75 (42–91) | NLR: 3 | 18.4 | OS, PFS |
| Vidal | 2018 | USA | 1991–2015 | 1826 | 61.8 ± 5.9 | NLR; lymphocyte; PLT; neutrophil; PLR | 68 | OS, RFS |
| Sun | 2018 | China | 2011–2016 | 171 | Unclear | NLR: 2.31; PLR:134 | 24 | OS, DFS |
| Uemura | 2017 | Japan | 2014–2016 | 47 | 71.0 ± 7.0 | NLR: 3.83 | Unclear | OS |
| Mehra | 2017 | UK | Unclear | 75 | Unclear | NLR: 2.6 | 25.6 | OS, PFS |
| Boegemann | 2017 | USA | 2009–2015 | 96 | 70 (63.0–76.3) | NLR: 5 | 20 | OS, PFS |
| Pei | 2017 | China | 2013–2017 | 111 | 71 (43–86) | NLR: 3.3 | 16 | OS, PFS |
| Buttigliero | 2017 | Italy | Unclear | 110 | Unclear | NLR: 3 | 31.7 | OS, PFS |
| Wang | 2017 | China | 2010–2014 | 290 | 71 (65–77) | Monocyte:0.425 | 37.0 | OS, PFS |
| Jang | 2016 | Korea | 2000–2010 | 2067 | 66 (61–70) | NLR:1.76; lymphocyte, neutrophil | 78 | OS, RFS, CSS |
| Lolli | 2016 | Italy | 2011–2015 | 230 | 74 (45–90) | NLR: 3; PLR:210 | 29 | OS |
| Shigeta | 2016 | Japan | 2007–2015 | 108 106 |
71 (57–88) 73 (52–95) |
NLR: 3.8; LMR: 3.86; monocyte: 0.4 | Unclear | OS, PFS |
| Lee | 2016 | Korea | Unclear | 1367 | 65.6 (45–82) | NLR: 2.5 | 57 | RFS |
| Wang | 2016 | China | 2010–2014 | 290 | 75 (67–79) | Lymphocyte; PLT:190.5; PLR:117.58 | 37 | OS, PFS, CSS |
| Langsenlehner | 2015 | Austria | 1999–2007 | 415 | 66.9 ± 7.2 | NLR: 5 | 87 | OS, PFS, DMFS |
| Langsenlehner | 2015 | Austria | 1999–2007 | 374 | 68 ± 7.1 | NLR; PLT; PLR:190 | 87 | OS, CSS, DMFS |
| Zhang | 2015 | China | 2006–2009 | 237 | Unclear | NLR: 2.36 | 46.6 | RFS |
| Bahig | 2015 | Canada | 2001–2014 | 950 | Unclear | NLR; lymphocyte; neutrophil | 44 | OS, RFS |
| Lorente | 2015 | UK | Unclear | 755 | 67 (62–73) | NLR: 3 | 12.8 | OS, PFS |
| Yao | 2015 | Japan | 2008–2014 | 57 | 74 (55–91) | NLR: 3.5 | 30 | OS, PFS |
| Li | 2015 | China | 2009–2012 | 103 | Unclear | PLR:150 | 36 | OS |
| McLachlan | 2015 | Austria | 2005–2012 | 42 | Unclear | NLR:5 | 23.1 | OS |
| Sharma | 2015 | USA | 1990–2007 | 8350 | Unclear | NLR:5 | 116.4 | OS, PFS, RFS, CSS |
| Templeton | 2014 | Canada | 2001–2011 | 357 | 71.0 (44.0–90.0) | NLR: 3 | Unclear | OS |
| Sonpavde | 2014 | UK | 2008–2010 | 848 | Unclear | NLR:2.5 | Unclear | OS, RFS |
| Nuhn | 2014 | USA | 1998–2010 | 238 | 68.3 (44.6–84.5) | NLR: 3 | 15.0 | OS |
| Poyet | 2013 | Switzerland | 2008–2013 | 399 | 64.0 (41.0–78.0) | NLR: 2.67 | 23.0 | RFS |
| Linton | 2013 | Austria | 2007–2009 | 184 | Unclear | NLR: 5 | Unclear | OS |
| Shafique | 2012 | UK | 2000–2007 | 897 | Unclear | NLR: 5 | 30 | OS |
| Yamada | 2011 | Japan | 1998–2006 | 104 | 74.2 ± 7.4 | PLT | 43 | CSS |
OS overall survival, CSS cancer-specific survival, PFS progression-free survival, DMFS distant metastases-free survival, RFS recurrence-free survival, PLR platelet to lymphocyte ratio, NLR neutrophil to lymphocyte ratios, LMR lymphocyte to monocyte ratio, PLT platelet